RIL Inhibitors
Chemical inhibitors of RIL function by targeting various signaling pathways and kinases that are likely involved in its activity. Staurosporine, a potent inhibitor of protein kinases, can disrupt the signaling pathways essential for RIL's function, leading to its inhibition. This broad-spectrum kinase inhibition affects multiple pathways simultaneously, which may include those that RIL is a part of. Bisindolylmaleimide I and GF109203X, both specific inhibitors of protein kinase C (PKC), can lead to reduced phosphorylation of proteins within pathways where RIL is involved. Since PKC is responsible for phosphorylating various substrates, its inhibition results in altered signaling cascades, affecting RIL's role in these pathways. Similarly, H-89 targets protein kinase A (PKA), and by inhibiting PKA, the phosphorylation of target substrates involved in the same pathways as RIL is reduced, potentially disrupting RIL's functional role.
LY294002 and Wortmannin are inhibitors of phosphoinositide 3-kinases (PI3K), which are part of the Akt signaling pathway, a pathway that RIL may intersect with. Inhibition of PI3K by these chemicals can disrupt signaling cascades relevant to RIL's function. PD98059 and U0126 both inhibit MEK1/2, which is upstream of the ERK pathway, a pathway that can involve RIL. By inhibiting MEK1/2, ERK1/2 activation is prevented, which can result in the functional inhibition of RIL. SB203580 targets p38 MAP kinase, and by inhibiting this kinase, it can affect downstream pathways that involve RIL. PP2, an Src family kinase inhibitor, can inhibit the phosphorylation of a variety of substrates, including those in pathways where RIL operates. SP600125, an inhibitor of c-Jun N-terminal kinase (JNK), affects cellular processes that RIL may be part of, leading to a decrease in RIL activity. Lastly, Y-27632 inhibits the Rho-associated protein kinase (ROCK), which can alter the actin cytoskeleton and cell motility pathways regulated by ROCK, pathways where RIL may play a role, thereby inhibiting its function.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent protein kinase inhibitor. RIL, as a LIM domain protein, is thought to be involved in protein-protein interactions, potentially with kinases. Staurosporine's broad inhibition of kinases can disrupt signal transduction pathways that are necessary for RIL's function, leading to its inhibition. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I specifically inhibits protein kinase C (PKC). Since PKC can phosphorylate various substrates, its inhibition can lead to reduced phosphorylation of proteins within pathways where RIL is involved, thereby inhibiting RIL function where phosphorylation is a regulatory mechanism. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits phosphoinositide 3-kinases (PI3K). As PI3K is involved in the Akt signaling pathway, which can intersect with pathways involving RIL, inhibition of this kinase can disrupt signaling cascades relevant to RIL function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 selectively inhibits mitogen-activated protein kinase kinase 1 (MEK1), which is upstream of the ERK pathway. As RIL can be part of signaling pathways that involve ERK, inhibition of MEK1 can lead to functional inhibition of RIL. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAP kinase inhibitor. By inhibiting p38 MAP kinase, this compound can inhibit downstream pathways that involve RIL, leading to its functional inhibition. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an Src family kinase inhibitor. Src kinases can phosphorylate a variety of substrates, potentially including those in pathways where RIL is active. Inhibition of Src kinases could therefore inhibit RIL function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor. By halting PI3K activity, the Akt pathway can be inhibited. Since RIL may interact with proteins in the Akt pathway, wortmannin can inhibit RIL's function by hindering those interactions. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). JNK is involved in various cellular processes that could intersect with RIL function, and its inhibition could lead to a decrease in RIL's activity in these processes. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 inhibits MEK1/2, preventing the activation of ERK1/2. As RIL could function in pathways that involve ERK signaling, inhibition of MEK1/2 by U0126 can result in functional inhibition of RIL. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a selective inhibitor of the Rho-associated protein kinase (ROCK). RIL, as a LIM domain-containing protein, could interact with the actin cytoskeleton and cell motility pathways regulated by ROCK. Inhibition of ROCK by Y-27632 could alter those pathways and inhibit RIL's function. | ||||||